| Symbol | RLMD |
|---|---|
| Name | RELMADA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2222 PONCE DE LEON BOULEVARD,FLOOR 3, CORAL GABLES, Florida, 33134, United States |
| Telephone | +1 786 629-1376 |
| Fax | — |
| — | |
| Website | https://www.relmada.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001553643 |
| Description | Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. Additional info from NASDAQ: |
New Form SCHEDULE 13G - RELMADA THERAPEUTICS, INC. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001104659-26-076490 <b>Size:</b> 16 KB
Read moreRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Read moreRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Read moreNew Form SCHEDULE 13G - RELMADA THERAPEUTICS, INC. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001738048-26-000066 <b>Size:</b> 35 KB
Read more(99% Neutral) RELMADA THERAPEUTICS, INC. (RLMD) Announces Regulatory Update
Read moreRelmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Read moreNew Form S-3ASR - RELMADA THERAPEUTICS, INC. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001213900-26-055901 <b>Size:</b> 558 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06009003 | Individual Patient Esmethadone (REL-1017) Expanded Access Program | — | Major Depressive Disorder | Temporarily_Not_Available | — | — | ClinicalTrials.gov |
| NCT07342517 | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresp… | Phase3 | Bladder (Urothelial, Transitional Cell) Cancer | Withdrawn | 2026-06-30 | 2028-06-30 | ClinicalTrials.gov |
| NCT07464145 | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants Wit… | Phase3 | Bladder (Urothelial, Transitional Cell) Cancer | Not_Yet_Recruiting | 2026-06-01 | 2032-09-01 | ClinicalTrials.gov |
| NCT07313891 | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Tr… | Phase3 | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Withdrawn | 2026-05-01 | 2029-11-01 | ClinicalTrials.gov |
| NCT06663137 | Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade… | Phase2 | Non Muscle Invasive Bladder Cancer | Recruiting | 2024-08-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT05081167 | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major … | Phase3 | Major Depressive Disorder | Completed | 2021-06-02 | 2022-09-14 | ClinicalTrials.gov |
| NCT04855760 | Safety of REL-1017 for Major Depressive Disorder | Phase3 | Major Depressive Disorder | Completed | 2021-04-01 | 2023-07-27 | ClinicalTrials.gov |
| NCT04688164 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment f… | Phase3 | Major Depressive Disorder | Completed | 2021-01-08 | 2022-11-10 | ClinicalTrials.gov |
| NCT03051256 | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 2… | Phase2 | Depressive Disorder, Major | Completed | 2018-05-11 | 2019-09-30 | ClinicalTrials.gov |
| NCT03638869 | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1… | Phase1 | Neuropathic Pain | Completed | 2015-08-31 | 2015-11-16 | ClinicalTrials.gov |
| NCT03637361 | Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017… | Phase1 | Neuropathic Pain | Completed | 2014-12-04 | 2015-06-02 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT03638869 |
| REL-1017 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT03638869 |
| Placebo | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT03637361 |
| REL-1017 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT03637361 |
| Placebo | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT03051256 |
| REL-1017 | Other | Phase PHASE2 | Depressive Disorder, Major | COMPLETED | NCT03051256 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT05081167 |
| REL-1017 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT05081167 |
| REL-1017 | Other | Preclinical | Major Depressive Disorder | TEMPORARILY_NOT_AVAILABLE | NCT06009003 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04688164 |
| REL-1017 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04688164 |
| REL-1017 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04855760 |
| NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Other | Phase PHASE2 | Non Muscle Invasive Bladder Cancer | RECRUITING | NCT06663137 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | DRUG | Phase PHASE3 | Bladder (Urothelial, Transitional Cell) Cancer | NOT_YET_RECRUITING | NCT07464145 |
| NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | DRUG | Phase PHASE2 | Non Muscle Invasive Bladder Cancer | RECRUITING | NCT06663137 |
| Placebo | DRUG | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT06011577 |
| REL-1017 | DRUG | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT06011577 |